TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage immuno-oncology and RNA therapeutics company, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018, will also resign from the company's board of directors. He will continue to provide transition services to ensure a smooth handover. The company has named John Tattory as interim CFO, also effective immediately.
Tattory brings over 25 years of financial and operational leadership experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. Tattory's extensive background in life sciences finance positions him to guide TransCode through its next phase of growth.
The leadership change comes as TransCode Therapeutics continues to develop its pipeline of innovative cancer treatments. The company's lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The appointment of an interim CFO with deep financial and operational expertise is critical to maintaining momentum in clinical development and ensuring fiscal discipline.
Investors and stakeholders will be watching closely to see how the transition affects the company's financial strategy and operations. The news of Fitzgerald's retirement and Tattory's appointment was announced via a press release, which can be viewed in full at https://nnw.fm/8G3ik. Additionally, the latest news and updates relating to RNAZ are available in the company's newsroom at https://nnw.fm/RNAZ.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its focus on microRNA-10b and immune system mobilization represents a novel approach to cancer therapy. The company's success hinges on both scientific innovation and strong financial management, making the CFO transition a key event to monitor.
NetworkNewsWire (NNW), a specialized communications platform, distributed the announcement. NNW is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.NetworkNewsWire.com. Terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
